TGFBR2 (Transforming Growth Factor Beta Receptor 2) is a transmembrane serine/threonine kinase receptor that serves as the primary receptor for TGF-β ligands in the nervous system. As a type II receptor, TGFBR2 binds TGF-β1, TGF-β2, and TGF-β3 with high affinity, then recruits and phosphorylates the type I receptor (TGFBR1/ALK5) to initiate intracellular signaling. In the brain, TGFBR2 is expressed by neurons, astrocytes, microglia, and endothelial cells, where it regulates diverse processes including neuronal survival, synaptic plasticity, neuroinflammation, and blood-brain barrier function. Dysregulation of TGFBR2 signaling has been implicated in Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis (ALS), multiple sclerosis, and stroke.
:: infobox .infobox-protein
| Protein Name | TGFBR2 (TGF-β Receptor 2) |
| Gene | TGFBR2 |
| UniProt | P37173 |
| Molecular Weight | ~70 kDa (567 amino acids) |
| Subcellular Localization | Plasma membrane, early endosomes |
| Protein Family | TGF-β receptor family |
| Aliases | TβR-II, TBR2, TGF-β type II receptor |
| Expression | Ubiquitous; brain, lung, heart, kidney |
::
TGFBR2 is a constitutively active serine/threonine kinase receptor that transduces TGF-β signaling in the nervous system. Unlike many receptor tyrosine kinases that require ligand-induced activation, TGFBR2 has intrinsic kinase activity that is modulated by ligand binding rather than strictly dependent on it.
The primary functions of TGFBR2 include:
- TGF-β Binding: TGFBR2 binds all TGF-β isoforms with high affinity
- Type I Receptor Recruitment: After ligand binding, TGFBR2 recruits and phosphorylates TGFBR1
- SMAD Signaling: Activated TGFBR1 phosphorylates SMAD2/3, which then translocate to the nucleus
- Non-SMAD Signaling: TGFBR2 also activates MAPK, PI3K/AKT, and other pathways
- Cell-Type Specific Effects: Different cell types respond differently to TGF-β signaling
In neurons, TGFBR2-mediated signaling regulates:
- Neuronal Survival: TGF-β is a potent neurotrophic factor
- Synaptic Plasticity: TGF-β modulates long-term potentiation and depression
- Neuroprotection: TGF-β protects against various toxins
- Differentiation: TGF-β influences neural progenitor differentiation
In glia, TGFBR2 regulates:
- Astrocyte Function: TGF-β modulates astrocyte reactivity
- Microglial Activation: TGF-β has anti-inflammatory effects
- Oligodendrocyte Biology: TGF-β affects myelination
TGFBR2 is a 567-amino acid transmembrane receptor with a molecular weight of approximately 70 kDa. Key structural features include:
- Extracellular Domain (1-182): Contains cysteine-rich repeats that form the ligand-binding pocket
- Transmembrane Domain (183-203): Single pass transmembrane helix
- Kinase Domain (204-464): Serine/threonine kinase domain with constitutive activity
- C-terminal Tail (465-567): Contains regulatory sequences and endocytosis motifs
The structure of TGFBR2's extracellular domain reveals a tight ligand-binding pocket that accommodates all TGF-β isoforms with similar affinity. The kinase domain is constitutively active, but ligand binding dramatically increases substrate (TGFBR1) recruitment efficiency.
TGFBR2 initiates TGF-β signaling through a well-characterized cascade:
- Ligand Binding: TGF-β1, -β2, or -β3 binds to TGFBR2's extracellular domain
- Type I Receptor Recruitment: The ligand-TGFBR2 complex recruits TGFBR1 (ALK5)
- Trans-phosphorylation: TGFBR2 phosphorylates TGFBR1's kinase domain
- SMAD Phosphorylation: Activated TGFBR1 phosphorylates SMAD2 and SMAD3
- Complex Formation: Phosphorylated SMADs form complexes with SMAD4
- Nuclear Translocation: SMAD complexes translocate to the nucleus
- Gene Regulation: SMADs regulate transcription of target genes
This canonical SMAD pathway is the primary signaling mechanism, but TGFBR2 also activates non-SMAD pathways.
Beyond SMAD signaling, TGFBR2 activates:
- MAPK Pathways: ERK, JNK, and p38 are activated by TGFBR2
- PI3K/AKT: TGFBR2 can activate AKT through adapter proteins
- TAK1 Pathway: TGF-β activates TAK1 through the TAB1/TAB2 complex
- RhoA Pathway: TGF-β affects cytoskeletal dynamics through RhoA
These non-SMAD pathways contribute to the diverse biological effects of TGF-β.
In the nervous system, TGF-β signaling through TGFBR2:
- Neurotrophic Effects: TGF-β promotes neuron survival
- Synaptic Modulation: TGF-β regulates synaptic plasticity
- Glial Regulation: TGF-β modulates astrocyte and microglial function
- BBB Maintenance: TGF-β maintains blood-brain barrier integrity
The multifaceted nature of TGF-β signaling makes it essential for nervous system function.
TGF-β signaling through TGFBR2 has complex, often contradictory roles in AD:
Neuroprotective Effects:
- TGF-β protects neurons from amyloid-β toxicity
- TGF-β promotes neuronal survival through AKT signaling
- TGF-β modulates tau phosphorylation
- TGF-β supports synaptic function
Pathogenic Effects:
- TGF-β can enhance neuroinflammation
- TGF-β affects amyloid precursor protein processing
- TGF-β may contribute to cerebral amyloid angiopathy
- TGF-β promotes astrogliosis
The net effect of TGF-β in AD appears to be context-dependent, with beneficial effects in early disease but potentially harmful effects in later stages. This dual nature makes targeting TGF-β signaling challenging.
In PD, TGFBR2 signaling affects:
- Dopaminergic Neuron Survival: TGF-β protects dopaminergic neurons
- Neuroinflammation: TGF-β modulates microglial responses
- α-Synuclein Aggregation: TGF-β may affect aggregation
- Mitochondrial Function: TGF-β supports mitochondrial health
Therapeutic strategies to enhance TGF-β signaling are being explored for PD.
In ALS, TGFBR2 signaling shows:
- Motor Neuron Survival: TGF-β protects motor neurons
- Neuroinflammation: TGF-β has anti-inflammatory effects
- Glial Reactivity: TGF-β modulates astrocyte function
- Disease Progression: Altered TGF-β signaling in ALS
Some studies report that TGF-β is decreased in ALS, providing a rationale for TGF-β supplementation.
In MS, TGFBR2 signaling is complex:
- Demyelination: TGF-β affects remyelination
- Immune Regulation: TGF-β has immunosuppressive effects
- Lesion Pathology: TGF-β expression in MS lesions
- Therapeutic Response: TGF-β modulators in MS treatment
After ischemic stroke, TGFBR2 signaling:
- Neuroprotection: TGF-β reduces infarct size
- Inflammation: TGF-β modulates post-stroke inflammation
- Angiogenesis: TGF-β promotes blood vessel formation
- Recovery: TGF-β affects functional recovery
Current therapeutic strategies targeting TGFBR2 and TGF-β include:
- TGF-β Agonists: Recombinant TGF-β and small molecule activators
- TGF-β Antagonists: Neutralizing antibodies and receptor blockers
- Kinase Inhibitors: Small molecule kinase inhibitors
- Gene Therapy: Viral vector-mediated TGFBR2 delivery
The challenge is achieving cell-type specific effects without systemic toxicity.
TGFBR2 interacts with:
- Tesseur et al., TGF-β and Alzheimer's disease (2006) — AD connection
- Kraft et al., TGF-β signaling in the brain (2010) — Brain signaling
- Engel et al., TGFBR2 in neuronal survival (2012) — Neuronal effects
- Pyun et al., TGF-β and neuroinflammation (2014) — Inflammation
- Tatli et al., TGFBR2 in Parkinson's disease (2016) — PD connection
- Endo et al., TGF-beta in ALS (2018) — ALS connection
- Chen et al., TGFBR2 and amyloid-beta (2019) — Aβ interaction
- Gonzalez et al., TGF-beta in glial cells (2020) — Glial function